Too bad Martha Stewart and Sam Waksal weren't more patient with their investments in scandal-plagued ImClone Systems Inc. On Monday, the company's share price soared past pre-scandal levels and ...

TRENTON, N.J. — Biotechnology company ImClone Systems Inc. said Wednesday it is considering a buyout offer worth $70 per share from an unidentified large pharmaceutical company, and rejected a ...

A $70 a share offer would represent a premium of 51 percent over ImClone's closing price of $46.44 on July 30, the day before Bristol-Myers announced its $60 a share offer.

They also questioned whether a Merrill broker may have executed a rapid-fire series of ImClone stock purchases in late December intended to prop up the company's share price and allow ImClone ...

ImClone Systems yesterday said it turned down a $36-a-share bid last month from a major drugmaker, after billionaire investor Carl Icahn opposed the sale. Icahn, locked in a battle with ImClone ...

Eli Lilly says it plans to buy cancer-drug developer ImClone Systems for $70 a share, or about $6.5 billion, in an all-cash deal that is not subject to any financing conditions.

Eli Lilly and Company announced that its wholly-owned subsidiary, Alaska Acquisition Corporation, has commenced its tender offer for all outstanding shares of ImClone Systems Incorporated at a price ...

Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash Offer Represents Approximately 30% Premium to the Closing Price of ImClone's Stock on July 30, Approximately ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

ImClone Systems Inc said on Wednesday it has received a takeover offer of $70 a share from a large pharmaceutical company, topping an earlier bid of $60 a share from Bristol-Myers Squibb Co and ...

ImClone Systems Inc <IMCL.O> said on Wednesday it has received a takeover offer of $70 a share from a large pharmaceutical company, topping an earlier bid of $60 a share from Bristol-Myers Squibb ...